NCT06573281 - A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years | Biotech Hunter

Enrollment

213

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

April 13, 2026

Study Completion Date

April 13, 2026

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

Investigational RSV vaccine 1

Investigational RSV vaccine 1 administered intramuscularly on Day 1 and Day 30.

BIOLOGICAL

Investigational RSV vaccine 2

Investigational RSV vaccine 2 administered intramuscularly on Day 1 and Day 30.

BIOLOGICAL

Investigational RSV vaccine 3

Investigational RSV vaccine 3 administered intramuscularly on Day 1 and Day 30.

BIOLOGICAL

Investigational RSV vaccine 4

Investigational RSV vaccine 4 administered intramuscularly on Day 1 and Day 30.

BIOLOGICAL

Investigational RSV vaccine 5

Investigational RSV vaccine 5 administered intramuscularly on Day 1 and Day 30.

BIOLOGICAL

Investigational RSV vaccine 6

Investigational RSV vaccine 6 administered intramuscularly on Day 1.

DRUG

Placebo

Placebo administered intramuscularly on Day 1 and Day 30 and for RSV\_Group F placebo administered only on Day 30.

Trial Locations (9)

3124

GSK Investigational Site, Camberwell

14609

GSK Investigational Site, Rochester

28006

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28222

GSK Investigational Site, Madrid

30281

GSK Investigational Site, Atlanta

66219

GSK Investigational Site, Lenexa

68134

GSK Investigational Site, Omaha

90274

GSK Investigational Site, Rolling Hills Estates